Does the addition of a second antipsychotic drug improve clozapine treatment?

Schizophrenia Bulletin

Volumn 35, Issue 2, 2009, Pages 458-468

  Barbui, Corrado ^a   Signoretti, Alessandra ^a   Mule, Serena ^a   Boso, Marianna ^a,b   Cipriani, Andrea ^a  

^a UNIVERSITY OF VERONA   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

Author keywords

Clozapine; Combination strategies; Schizophrenia

Indexed keywords

AMISULPRIDE; BENZAMIDE; CHLORPROMAZINE; CLOZAPINE; PHENOTHIAZINE; PIPOTIAZINE; PLACEBO; RISPERIDONE; SULPIRIDE;

ARTICLE; CLINICAL RESEARCH; CLINICAL TRIAL; DRUG EFFICACY; DRUG EXPOSURE; DRUG RESEARCH; DRUG TREATMENT FAILURE; HUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSYCHOSIS; SYSTEMATIC REVIEW;

ANTIPSYCHOTIC AGENTS; CLOZAPINE; DATABASES AS TOPIC; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME;

EID: 65349163482     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbn030     Document Type: Article

References (48)

1. Conley RR, Kelly DL. Management of treatment resistance in schizophrenia. Biol Psychiatry. 2001;50:898-911.
2. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988;45:789-796.
3. Rosenheck R, Cramer J, Xu W, et al. A comparison of cloza-pine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. N Engl J Med. 1997;337:809-815.
4. Wahlbeck K, Cheine M, Essali A, Adams C. Evidence of clo-zapine's effectiveness in schizophrenia: a systematic review and meta-analysis of randomized trials. Am J Psychiatry. 1999;156:990-999.
5. Hennen J, Baldessarini RJ. Suicidal risk during treatment with clozapine: a meta-analysis. Schizophr Res. 2005;73(2-3): 139-145.
6. Chakos M, Lieberman J, Hoffman E, Bradford D, Sheitman B. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. Am J Psychiatry. 2001;158:518-526.
7. Sernyak MJ, Rosenheck R. Clinicians' reasons for antipsy-chotic coprescribing. J Clin Psychiatry. 2004;65:1597-1600.
8. American Psychiatric Association.Practice guideline for the treatment of patients with schizophrenia. Am J Psychiatry. 1997;154:4 suppl1-63.
9. National Collaborating Centre for Mental Health.Schizophre-nia. Core Interventions in the Treatment and Management of Schizophrenia in Primary and Secondary Care. NICE Guidelines 2002;London, UKNational Institute for Clinical Excellence.
10. Miller AL, Hall CS, Buchanan RW, et al. The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update. J Clin Psychiatry. 2004;65:500-508.
11. Clinical practice guidelines. Treatment of schizophrenia. Can J Psychiatry. ;13 suppl 17S-57S.
12. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of reporting of meta-analyses. Lancet. 1999;354:1896-1900.
13. Norman GR. Issues in the use of change scores in randomized trials. J Clin Epidemiol. 1989;42:1097-1105.
14. Altman DG, Bland JM. Detecting skewness from summary information. BMJ. 1996;313:1200.
15. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17:1-12.
16. Moher D, Pham B, Jones A, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet. 1998;352:609-613.
17. WHO Collaborating Centre for Drug Statistic Methodology. Guidelines for ATC Classification and DDD Assignment. Oslo, Norway WHO; 2003.
18. Patten S, Cipriani A, Brambilla P, Nose M, Barbui C. International dosage differences in fluoxetine clinical trials. Can J Psychiatry. 2005;50:31-38.
19. Higgins J, Green S. Cochrane Handbook for Systematic Reviews of Interventions 4.2.6. Chichester, UK: John Wiley & Sons, Ltd.; 2006.
20. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557-560.
21. Ioannidis JP, Trikalinos TA. The appropriateness of asymmetry tests for publication bias in meta-analyses: a large survey. CMAJ. 2007;176:1091-1096.
22. Paton C, Whittington C, Barnes TR. Augmentation with a second antipsychotic in patients with schizophrenia who partially respond to clozapine: a meta-analysis. J Clin Psycho-pharmacol. 2007;27:198-204.
23. Kreinin A, Novitski D, Weizman A. Amisulpride treatment of clozapine-induced hypersalivation in schizophrenia patients: a randomized, double-blind, placebo-controlled cross-over study. Int Clin Psychopharmacol. 2006;21:99-103.
24. Cha C, Hui G, Quing G. Evaluation of therapeutic effect with chlorpromazine and clozapine for treatment of schizophrenia. Xinxiang Med Stud. 1999;16:311-316.
25. Freudenreich O, Henderson DC, Walsh JP, Culhane MA, Goff DC. Risperidone augmentation for schizophrenia partially responsive to clozapine: a double-blind, placebo-controlled trial. Schizophr Res. 2007;92:90-94.
26. Honer WG, Thornton AE, Chen EY, et al. Clozapine alone versus clozapine and risperidone with refractory schizophrenia. N Engl J Med. 2006;354:472-482.
27. Jia Z, Zhang Z, Jin S. A controlled trial for comparing cloza-pine combined with pipothiazine palmitate to clozapine alone in the treatment of negative symptoms in schizophrenic patients. Herald Med. 2000;19:142-143.
28. Josiassen RC, Joseph A, Kohegyi E, et al. Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial. Am J Psychiatry. 2005;162:130-136.
29. Liu Q, Li X, Zhang Y. A control study of clozapine in combination with sulpiride in alleviating the negative symptoms of schizophrenia. Chin J Psychiatry. 1996;29:87-90.
30. Liu Q, Li X. A comparative study on the efficacy of combining risperidone and clozapine in the treatment of schizophrenia. Shandong Arch Psychiatry. 2001;14:28-30.
31. Ni J, Jang L, Hong X. Therapeutic effects of clozapine, ris-peridone and their combination in the treatment of schizophrenia. Health Psychol J. 2001;3:181-182.
32. Peng H, Kuang Y, Huang X. A control study of risperidone in combination with clozapine in treating refractory schizophrenia. J Mod Clin Med Bioeng. 2002;7:100-102.
33. Si S, Yuan C. A comparative trial of the effects of sulpiride combined with clozapine in the treatment of schizophrenia. Shandong Arch Psychiatry. 1999;12:17-20.
34. Shiloh R, Zemishlany Z, Aizenberg D, et al. Sulpiride augmentation in people with schizophrenia partially responsive to clozapine. A double-blind, placebo-controlled study. Br J Psychiatry. 1997;171:569-573.
35. Wang C, Qin T, Lin Y, Zhao X. A clinical effect and follow-ing-up study about sulpiride and clozapine for 105 cases of the schizophrenia type. Xinxiang Med Stud. 1994;11:148-151.
36. Wu L. A control study of risperidone and clozapine combination for the treatment of refractory schizophrenia. Health Psychol J. 2002;10:135-137.
37. Xao H. A double-blind comparative study of the effects of sulpiride combined with clozapine in the treatment of schizophrenia. Sichuan Ment Health. 1999;12:250-251.
38. Xin X, Du B, Zeng Z. A controlled clinical study of risperi-done and low dose of clozapine in treating schizophrenia. Herald Med. 2001;20:501-502.
39. Yagcioglu AE, Kivircik Akdede BB, Turgut TI, et al. A double-blind controlled study of adjunctive treatment with risperi-done in schizophrenic patients partially responsive to clozapine: efficacy and safety. J Clin Psychiatry. 2005;66:63-72.
40. Yue H, Song L, Xu Y. A comparative trial of risperidone in the treatment of schizophrenia over two years. Shangai Arch Psychiatry. 2004;16:165-167.
41. Zhu Y, Zhang S, Zhang D. A controlled trial comparing chlorimipramine and sulpiride as adjunct to clozapine in the treatment of negative symptoms of schizophrenia. J Clin Psy-chol Med. 1999;9:204-205.
42. Zhu H, Deng D. A study of clozapine combined with or without pipotiazine palmitate in refractory schizophrenia. J Clin Psychol Med. 2002;12:15-17.
43. Zou G, Huang Y, Zou S, Yang Y. A comparative trial of the beneficial effects of sulpiride combined with clozapine in the treatment of refractory schizophrenia. J Yichun Univ. 2003;25:94-96.
44. Chakrabarti A, Adams CE, Rathbone J, et al. Schizophrenia trials in China: a survey. Acta Psychiatr Scand. 2007;116:6-9.
45. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA. 1995;273:408-412.
46. Day SJ, Altman DG. Statistics notes: blinding in clinical trials and other studies. BMJ. 2000;321:504.
47. Ioannidis JP, Patsopoulos NA, Evangelou E. Uncertainty in heterogeneity estimates in meta-analyses. BMJ. 2007;335:914-916.
48. Mule S, Cipriani A, Barbui C. Aripiprazole in addition to clo-zapine in partially responsive patients with schizophrenia. A critical review of case series. Clin Schizophr Relat Psychoses. 2008;1:341-347.